Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)

NCT02459119 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)

Interventions

DRUG: Regorafenib

Sponsor

University of Alabama at Birmingham

Collaborators

[object Object]